Previous studies have reported that anti-PD-1 immunotherapy could re-invigorate the effector function of CD8+ T cells in TME, which triggered tumor cell ferroptosis by secreting IFN-γ and suppressing the expression of subunits of the glutamate-cystine antiporter system Xc−. The gene discussed is PDCD1; the disease is neoplasm.